将FOXM1和PD-L1与CDK4/6-MEK向治疗的耐药性联系在一起,在恶性外围神经膜瘤中
Joshua J Lingo1,2, Ellen Voigt1,2,3, Dawn E Quelle1,2,3,4,5
1Cancer Biology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.
Oncotarget
|September 30, 2024
概括
向CDK4/6,MEK和PD-L1对恶性外围神经膜瘤 (MPNSTs) 显示出前景. 对FOXM1的进一步研究可能会克服耐药性并增强对MPNSTs的免疫反应.
科学领域:
- 在瘤学瘤学.
- 癌症免疫学 癌症免疫学
- 分子生物学分子生物学
背景情况:
- 恶性外围神经膜瘤 (MPNSTs) 是一种缺乏有效治疗的侵袭性瘤.
- MPNSTs是由Ras过度激活,NF1损失和MEK/CDK4/6通路激活驱动的.
研究的目的:
- 在MPNST中研究CDK4/6,MEK和PD-L1联合抑制的疗效.
- 探索用向疗法治疗的MPNST中耐药性和免疫调节的机制.
主要方法:
- 使用了MPNSTs的临床前小鼠模型.
- 使用针对CDK4/6,MEK和PD-L1.1的组合疗法.
- 分析瘤免疫微环境的变化,包括血细胞的积累.
主要成果:
- 双重CDK4/6-MEK抑制显示出有效性,通过PD-L1向增强.
- 三重组合治疗导致了MPNST回归和改善的生存率,但最终的耐药性.
- 抑制CDK4/6-MEK诱导了与内血细胞的独特免疫激活.
结论:
- PD-L1和FOXM1相互关联,可能会调解对CDK4/6-MEK疗法的耐药性.
- FOXM1可能会抑制抗瘤免疫力,阻碍免疫治疗的有效性.
- 针对CDK4/6,MEK,PD-L1和FOXM1网络提供了潜在的未来MPNST治疗策略.
更多相关视频
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
1.9K
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
1.7K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
